Skip to main content
American College of Cardiology Annual Meeting
newsroom
Menu
Menu
Main navigation
Home
Education
Featured Diseases & Conditions
Acute Hepatic Porphyria
Alzheimer Disease
Chronic Lymphocytic Leukemia
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Job Board
Search
Contact
Login
Menu
Menu
Main navigation
Home
Education
Featured Diseases & Conditions
Acute Hepatic Porphyria
Alzheimer Disease
Chronic Lymphocytic Leukemia
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Job Board
Advertisement
Pop Quiz
EPA Treatment and CV Outcomes
Copied to clipboard
<section><h2></h2></section><section><h2><h2><p>Ture or False: Patients with established atherosclerosis or diabetes, cardiovascular risk factors, and triglyceride levels greater than or equal to 135 mm/dL who are receiving the highest levels of on-treatment eicosapentaenoic acid (EPA) will likely experience an increase in new heart failure and hospitalization for heart failure.</p></h2></h2></section><section><h2><h2><p>“In the overall REDUCE-IT trial, there was a numerically lower rate of heart failure, but this wasn’t statistically significant. However, in these EPA analyses, we see that patients at the highest levels of on-treatment EPA, there was indeed a significant reduction in new heart failure and hospitalization for heart failure,” said Dr Bhatt. “Thus, we see in REDUCE-IT EPA, the full extent of ischemic events and now also heart failure are significantly correlated with higher levels of on-treatment EPA.”</p><p> </p><p>Watch Dr Bhatt provide insight into the results in this <a href="https://www.consultant360.com/video/cardiology/highlighting-epa-levels-and-cardiovascular-outcomes-reduce-it">video</a>. Or read the video transcript <a href="https://www.consultant360.com/cardiology/transcript-highlighting-epa-levels-and-cardiovascular-outcomes-reduce-it">here</a>.</p><p><strong></strong></p></h2></h2><p></p></section><section><h3><h2><p>“In the overall REDUCE-IT trial, there was a numerically lower rate of heart failure, but this wasn’t statistically significant. However, in these EPA analyses, we see that patients at the highest levels of on-treatment EPA, there was indeed a significant reduction in new heart failure and hospitalization for heart failure,” said Dr Bhatt. “Thus, we see in REDUCE-IT EPA, the full extent of ischemic events and now also heart failure are significantly correlated with higher levels of on-treatment EPA.”</p><p> </p><p>Watch Dr Bhatt provide insight into the results in this <a href="https://www.consultant360.com/video/cardiology/highlighting-epa-levels-and-cardiovascular-outcomes-reduce-it">video</a>. Or read the video transcript <a href="https://www.consultant360.com/cardiology/transcript-highlighting-epa-levels-and-cardiovascular-outcomes-reduce-it">here</a>.</p></h2></h3></section>
advertisement
Advertisement
Advertisement
